MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.960
+0.060
+2.07%
After Hours: 3.100 +0.14 +4.73% 18:05 05/27 EDT
OPEN
2.900
PREV CLOSE
2.900
HIGH
2.990
LOW
2.830
VOLUME
111.19K
TURNOVER
0
52 WEEK HIGH
15.08
52 WEEK LOW
2.100
MARKET CAP
60.79M
P/E (TTM)
-1.3352
1D
5D
1M
3M
1Y
5Y
Sellas' Ovarian Cancer Candidate Shows Clinical Benefit In Pretreated Patients
Benzinga · 2d ago
BRIEF-SELLAS Reports Preliminary Data From Phase 1/2 Clinical Trial Of WT1+ Advanced Ovarian Cancer Treatment
reuters.com · 2d ago
SELLAS Reports Prelim. Data Showing Clinical Benefits From Phase 1/2 Trial Of Galinpepimut-S In Combo With Keytruda For Advance Ovarian Cancer: Median Overall Survival Not Reached At A Median Follow Up Of 43.1 Weeks
  - Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a checkpoint
Benzinga · 2d ago
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor single agent study in a similar patient pop...
GlobeNewswire · 2d ago
SELLAS Life Sciences GAAP EPS of -$1.05, revenue of $1M
SELLAS Life Sciences press release (NASDAQ:SLS): Q1 GAAP EPS of -$1.05. Revenue of $1M (-82.5% Y/Y). Licensing revenue in the first quarter of 2022 was related to China’s NMPA approval
Seekingalpha · 05/12 20:28
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Top Premarket Gainers
MT Newswires · 05/10 08:18
BRIEF-SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
reuters.com · 04/26 13:13
More
No Data
Learn about the latest financial forecast of SLS. Analyze the recent business situations of Sellas Life Sciences Group Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SLS stock price target is 12.25 with a high estimate of 14.00 and a low estimate of 10.00.
High14.00
Average12.25
Low10.00
Current 2.960
EPS
Actual
Estimate
-0.85-0.64-0.42-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q4 2017
Institutional Holdings
Institutions: 44
Institutional Holdings: 10.48M
% Owned: 51.03%
Shares Outstanding: 20.54M
TypeInstitutionsShares
Increased
8
34.71K
New
3
35.04K
Decreased
8
84.13K
Sold Out
5
30.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Jane Wasman
President/Chief Executive Officer/Director
Angelos Stergiou
Executive Vice President/General Counsel/Secretary
Barbara Wood
Senior Vice President
Dragan Cicic
Chief Accounting Officer/Vice President - Finance/Controller
John Burns
Other
Robert Francomano
Director
David Scheinberg
Independent Director
Robert Van Nostrand
Independent Director
John Varian
No Data
No Data
About SLS
SELLAS Life Sciences Group, Inc. is a biopharmaceutical company that is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.